{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:14:59Z","timestamp":1780676099753,"version":"3.54.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["HHSF223201810255P"],"award-info":[{"award-number":["HHSF223201810255P"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>The purpose of this study is to show how the Ocular Compartmental Absorption &amp; Transit (OCAT\u2122) model in GastroPlus<jats:sup>\u00ae<\/jats:sup>can be used to characterize ocular drug pharmacokinetic performance in rabbits for ointment formulations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A newly OCAT\u2122 model developed for fluorometholone, as well as a previously verified model for dexamethasone, were used to characterize the aqueous humor (AH) concentration following the administration of multiple ointment formulations to rabbit. The model uses the following parameters: application surface area (SA), a fitted application time, and the fitted Higuchi release constant to characterize the rate of passage of the active pharmaceutical ingredient from the ointment formulations into the tears in vivo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Parameter sensitivity analysis was performed to understand the impact of ointment formulation changes on ocular exposure. While application time was found to have a significant impact on the time of maximal concentration in AH, both the application SA and the Higuchi release constant significantly influenced both the maximum concentration and the ocular exposure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This initial model for ointment ophthalmic formulations is a first step to better understand the interplay between physiological factors and ophthalmic formulation physicochemical properties and their impact on in vivo ocular drug pharmacokinetic performance in rabbits.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s11095-020-02965-y","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T23:29:02Z","timestamp":1605828542000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Ocular Physiologically Based Pharmacokinetic Modeling for Ointment Formulations"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2629-8039","authenticated-orcid":false,"given":"Maxime","family":"Le Merdy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Spires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viera","family":"Lukacova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Liang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Babiskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Bolger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,19]]},"reference":[{"key":"2965_CR1","unstructured":"Electronic Code of Federal Regulations (eCFR) [Internet]. Electronic Code of Federal Regulations (eCFR). 2020. Available from: https:\/\/www.ecfr.gov\/. Accessed 15 Mar 2020."},{"issue":"4","key":"2965_CR2","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1208\/s12248-016-9932-z","volume":"18","author":"SH Choi","year":"2016","unstructured":"Choi SH, Lionberger RA. Clinical, pharmacokinetic, and in vitro studies to support bioequivalence of ophthalmic drug products. AAPS J. 2016;18(4):1032\u20138.","journal-title":"AAPS J"},{"issue":"1","key":"2965_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11095-018-2537-8","volume":"36","author":"Y Harigaya","year":"2018","unstructured":"Harigaya Y, Jiang X, Zhang H, Chandaroy P, Stier EM, Pan Y. Bioequivalence study methods with pharmacokinetic endpoints for topical ophthalmic corticosteroid suspensions and effects of subject demographics. Pharm Res. 2018;36(1):13.","journal-title":"Pharm Res"},{"key":"2965_CR4","unstructured":"U.S. FDA. Draft guidance on tobramycin [internet]. 2019. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/Tobramycin%20ophthalmic%20ointment%200.3%20NDA%20050555%20PSG%20Page%20RC%20May%202019.pdf. Accessed 02 May 2020."},{"key":"2965_CR5","unstructured":"US. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations [Internet]. 2018. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/. Accessed 04 Aug 2020."},{"issue":"1\u20132","key":"2965_CR6","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.ijpharm.2015.07.066","volume":"493","author":"X Xu","year":"2015","unstructured":"Xu X, Al-Ghabeish M, Rahman Z, Krishnaiah YS, Yerlikaya F, Yang Y, et al. Formulation and process factors influencing product quality and in vitro performance of ophthalmic ointments. Int J Pharm. 2015;493(1\u20132):412\u201325.","journal-title":"Int J Pharm"},{"issue":"1","key":"2965_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1001\/archopht.1975.01010020046008","volume":"93","author":"R Hardberger","year":"1975","unstructured":"Hardberger R, Hanna C, Boyd CM. Effects of drug vehicles on ocular contact time. Arch Ophthalmol. 1975;93(1):42\u20135.","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"2965_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1755-3768.1989.tb00722.x","volume":"67","author":"G H\u00f8vding","year":"1989","unstructured":"H\u00f8vding G. A comparison between acyclovir and trifluorothymidine ophthalmic ointment in the treatment of epithelial dendritic keratitis. A double blind, randomized parallel group trial. Acta Ophthalmol (Copenh). 1989;67(1):51\u20134.","journal-title":"Acta Ophthalmol (Copenh)"},{"issue":"5","key":"2965_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/0039-6257(78)90178-9","volume":"22","author":"JS Robin","year":"1978","unstructured":"Robin JS, Ellis PP. Ophthalmic ointments. Surv Ophthalmol. 1978;22(5):335\u201340.","journal-title":"Surv Ophthalmol"},{"issue":"9","key":"2965_CR10","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1001\/archopht.1993.01090090062020","volume":"111","author":"KR Wilhelmus","year":"1993","unstructured":"Wilhelmus KR, Hyndiuk RA, Caldwell DR, Abshire RL, Folkens AT, Godio LB. 0.3% ciprofloxacin ophthalmic ointment in the treatment of bacterial keratitis. Arch Ophthalmol. 1993;111(9):1210\u20138.","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"2965_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ijpharm.2015.07.077","volume":"494","author":"X Xu","year":"2015","unstructured":"Xu X, Al-Ghabeish M, Krishnaiah YSR, Rahman Z, Khan MA. Kinetics of drug release from ointments: role of transient-boundary layer. Int J Pharm. 2015;494(1):31\u20139.","journal-title":"Int J Pharm"},{"key":"2965_CR12","doi-asserted-by":"crossref","unstructured":"Al-Ghabeish M, Xu X, Krishnaiah YSR, Rahman Z, Yang Y, Khan MA. Influence of drug loading and type of ointment base on the in vitro performance of acyclovir ophthalmic ointment. Int J Pharm. 20150;495(2):783\u201391.","DOI":"10.1016\/j.ijpharm.2015.08.096"},{"issue":"11","key":"2965_CR13","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1124\/dmd.115.065920","volume":"43","author":"JE Sager","year":"2015","unstructured":"Sager JE, Yu J, Ragueneau-Majlessi I, Isoherranen N. Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification. Drug Metab Dispos Biol Fate Chem. 2015;43(11):1823\u201337.","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"8","key":"2965_CR14","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/j.drudis.2019.04.002","volume":"24","author":"HJ Gukasyan","year":"2019","unstructured":"Gukasyan HJ, Hailu S, Karami TK, Graham R. Ocular biopharmaceutics: impact of modeling and simulation on topical ophthalmic formulation development. Drug Discov Today. 2019;24(8):1587\u201397.","journal-title":"Drug Discov Today"},{"issue":"2","key":"2965_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1208\/s12248-019-0408-9","volume":"22","author":"M Le Merdy","year":"2020","unstructured":"Le Merdy M, Tan M-L, Babiskin A, Zhao L. Physiologically based pharmacokinetic model to support ophthalmic suspension product development. AAPS J. 2020;22(2):26.","journal-title":"AAPS J"},{"issue":"5","key":"2965_CR16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/jps.2600670507","volume":"67","author":"KJ Himmelstein","year":"1978","unstructured":"Himmelstein KJ, Guvenir I, Patton TF. Preliminary pharmacokinetic model of pilocarpine uptake and distribution in the eye. J Pharm Sci. 1978;67(5):603\u20136.","journal-title":"J Pharm Sci"},{"issue":"12","key":"2965_CR17","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1002\/jps.2600651230","volume":"65","author":"JW Sieg","year":"1976","unstructured":"Sieg JW, Robinson JR. Mechanistic studies on transcorneal permeation of pilocarpine. J Pharm Sci. 1976;65(12):1816\u201322.","journal-title":"J Pharm Sci"},{"issue":"3","key":"2965_CR18","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/jps.2600750316","volume":"75","author":"HW Hui","year":"1986","unstructured":"Hui HW, Robinson JR. Effect of particle dissolution rate on ocular drug bioavailability. J Pharm Sci. 1986;75(3):280\u20137.","journal-title":"J Pharm Sci"},{"issue":"1","key":"2965_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0939-6411(97)00064-7","volume":"44","author":"N Worakul","year":"1997","unstructured":"Worakul N, Robinson JR. Ocular pharmacokinetics\/pharmacodynamics. Eur J Pharm Biopharm. 1997;44(1):71\u201383.","journal-title":"Eur J Pharm Biopharm"},{"issue":"11","key":"2965_CR20","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1007\/s11095-016-1993-2","volume":"33","author":"F Deng","year":"2016","unstructured":"Deng F, Ranta V-P, Kidron H, Urtti A. General pharmacokinetic model for topically administered ocular drug dosage forms. Pharm Res. 2016;33(11):2680\u201390.","journal-title":"Pharm Res"},{"issue":"Pt B","key":"2965_CR21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejpb.2015.01.003","volume":"95","author":"EM del Amo","year":"2015","unstructured":"del Amo EM, Vellonen K-S, Kidron H, Urtti A. Intravitreal clearance and volume of distribution of compounds in rabbits: In silico prediction and pharmacokinetic simulations for drug development. Eur J Pharm Biopharm Off J Arbeitsgemeinschaft Pharm Verfahrenstechnik EV. 2015;95(Pt B):215\u201326.","journal-title":"Eur J Pharm Biopharm Off J Arbeitsgemeinschaft Pharm Verfahrenstechnik EV"},{"issue":"8","key":"2965_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11095-018-2435-0","volume":"35","author":"M Lamminsalo","year":"2018","unstructured":"Lamminsalo M, Taskinen E, Karvinen T, Subrizi A, Murtom\u00e4ki L, Urtti A, et al. Extended pharmacokinetic model of the rabbit eye for Intravitreal and Intracameral injections of macromolecules: quantitative analysis of anterior and posterior elimination pathways. Pharm Res. 2018;35(8):153.","journal-title":"Pharm Res"},{"issue":"8","key":"2965_CR23","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1021\/acs.molpharmaceut.7b00164","volume":"14","author":"LA Hutton-Smith","year":"2017","unstructured":"Hutton-Smith LA, Gaffney EA, Byrne HM, Maini PK, Gadkar K, Mazer NA. Ocular Pharmacokinetics of Therapeutic Antibodies Given by Intravitreal Injection: Estimation of Retinal Permeabilities Using a 3-Compartment Semi-Mechanistic Model. Mol Pharm. 2017;14(8):2690\u20136.","journal-title":"Mol Pharm"},{"key":"2965_CR24","doi-asserted-by":"crossref","unstructured":"Bussing D, Shah DK. Development of a physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies in rabbits. J Pharmacokinet Pharmacodyn. 2020;47:597\u2013612.\u00a0","DOI":"10.1007\/s10928-020-09713-0"},{"key":"2965_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.addr.2017.12.008","volume":"126","author":"A-K Rimpel\u00e4","year":"2018","unstructured":"Rimpel\u00e4 A-K, Reinisalo M, Hellinen L, Grazhdankin E, Kidron H, Urtti A, et al. Implications of melanin binding in ocular drug delivery. Adv Drug Deliv Rev. 2018;126:23\u201343.","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"2965_CR26","first-page":"2251","volume":"34","author":"GM Grass","year":"1993","unstructured":"Grass GM, Lee VH. A model to predict aqueous humor and plasma pharmacokinetics of ocularly applied drugs. Invest Ophthalmol Vis Sci. 1993;34(7):2251\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"2965_CR27","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.xphs.2018.10.034","volume":"108","author":"RL Walenga","year":"2019","unstructured":"Walenga RL, Babiskin AH, Zhang X, Absar M, Zhao L, Lionberger RA. Impact of vehicle physicochemical properties on modeling-based predictions of cyclosporine ophthalmic emulsion bioavailability and tear film breakup time. J Pharm Sci. 2019;108(1):620\u20139.","journal-title":"J Pharm Sci"},{"issue":"4","key":"2965_CR28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1208\/s12248-019-0334-x","volume":"21","author":"M Le Merdy","year":"2019","unstructured":"Le Merdy M, Fan J, Bolger MB, Lukacova V, Spires J, Tsakalozou E, et al. Application of mechanistic ocular absorption modeling and simulation to understand the impact of formulation properties on ophthalmic bioavailability in rabbits: a case study using dexamethasone suspension. AAPS J. 2019;21(4):65.","journal-title":"AAPS J"},{"key":"2965_CR29","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1002\/jps.2600501018","volume":"50","author":"T Higuchi","year":"1961","unstructured":"Higuchi T. Rate of release of medicaments from ointment bases containing drugs in suspension. J Pharm Sci. 1961;50:874\u20135.","journal-title":"J Pharm Sci"},{"issue":"1","key":"2965_CR30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ijpharm.2011.03.051","volume":"418","author":"J Siepmann","year":"2011","unstructured":"Siepmann J, Peppas NA. Higuchi equation: derivation, applications, use and misuse. Int J Pharm. 2011;418(1):6\u201312.","journal-title":"Int J Pharm"},{"issue":"8","key":"2965_CR31","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/jps.2600730803","volume":"73","author":"GM Grass","year":"1984","unstructured":"Grass GM, Robinson JR. Relationship of chemical structure to corneal penetration and influence of low-viscosity solution on ocular bioavailability. J Pharm Sci. 1984;73(8):1021\u20137.","journal-title":"J Pharm Sci"},{"issue":"12","key":"2965_CR32","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1021\/js9802594","volume":"87","author":"MR Prausnitz","year":"1998","unstructured":"Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci. 1998;87(12):1479\u201388.","journal-title":"J Pharm Sci"},{"issue":"9","key":"2965_CR33","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/jps.2600700915","volume":"70","author":"JW Sieg","year":"1981","unstructured":"Sieg JW, Robinson JR. Mechanistic studies on Transcorneal permeation of Fluorometholone. J Pharm Sci. 1981;70(9):1026\u20139.","journal-title":"J Pharm Sci"},{"issue":"6","key":"2965_CR34","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/jps.2600640606","volume":"64","author":"JW Sieg","year":"1975","unstructured":"Sieg JW, Robinson JR. Vehicle effects on ocular drug bioavailability I: evaluation of Fluorometholone. J Pharm Sci. 1975;64(6):931\u20136.","journal-title":"J Pharm Sci"},{"issue":"9","key":"2965_CR35","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1023\/A:1018917729477","volume":"10","author":"AT Lu","year":"1993","unstructured":"Lu AT, Frisella ME, Johnson KC. Dissolution modeling: factors affecting the dissolution rates of polydisperse powders. Pharm Res. 1993;10(9):1308\u201314.","journal-title":"Pharm Res"},{"key":"2965_CR36","unstructured":"US. FDA. Pharmacology Review(s) NDA 50\u2013818 [Internet]. 2009. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/050818s000pharmr.pdf"},{"key":"2965_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.25004\/IJPSDR.2009.010101","volume":"1","author":"KS Rathore","year":"2009","unstructured":"Rathore KS, Nema RK. An insight into ophthalmic drug delivery system. Int J Pharm Sci Drug Res. 2009;1:1\u20135.","journal-title":"Int J Pharm Sci Drug Res"},{"key":"2965_CR38","unstructured":"US. FDA. Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro\/In Vivo Correlations [Internet]. 1997. Available from: https:\/\/www.fda.gov\/media\/70939\/download"},{"issue":"4","key":"2965_CR39","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1023\/A:1018922724566","volume":"10","author":"DE Wurster","year":"1993","unstructured":"Wurster DE, Buraphacheep V, Patel JM. The determination of diffusion coefficients in semisolids by Fourier transform infrared (FT-IR) spectroscopy. Pharm Res. 1993;10(4):616\u201320.","journal-title":"Pharm Res"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-020-02965-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-020-02965-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-020-02965-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T19:19:17Z","timestamp":1723922357000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-020-02965-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,19]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2965"],"URL":"https:\/\/doi.org\/10.1007\/s11095-020-02965-y","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,19]]},"assertion":[{"value":"5 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This article reflects the views of the authors and should not be construed to represent FDA\u2019s views or policies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}],"article-number":"245"}}